Literature DB >> 28352347

One mechanism of glucocorticoid action in asthma may involve the inhibition of IL-25 expression.

Wei Lu1, Chao Lu2, Chengming Zhang1, Chenghao Zhang1.   

Abstract

While the mechanism of action of classic cytokines in asthma has received increased attention from researchers, certain non-classical cytokines, such as IL-25, also participate in this mechanism. The present study was performed to investigate the changes in IL-25 (IL-17E) mRNA and protein in bronchial asthma and to further characterize the mechanism underlying the action of glucocorticoids in asthma. A total of 96 specific pathogen-free BALB/c male mice were randomly divided into three normal groups (after the first allergization, after the second allergization and after excitation), three asthma groups (with the same three subgroups), a dexamethasone group and a budesonide group (n=12/group). An asthma model was established via the ovalbumin-sensitized excitation method. Mice in the dexamethasone group received intraperitoneal injections of dexamethasone 1 h prior to each excitation, the budesonide group received a budesonide suspension via inhalation 2 h before and after each provocation, and the normal group was sensitized and challenged with isotonic saline. IL-25 protein expression levels in the bronchoalveolar lavage fluid were measured by ELISA, and the relative IL-25 mRNA content in lung tissue was determined by reverse transcription-quantitative polymerase chain reaction. Compared with the normal groups, both the protein and mRNA levels of IL-25 were significantly increased (P<0.05) in the asthma groups. Dexamethasone and budesonide groups exhibited significant protein and mRNA reductions in IL-25, as compared with the asthma group after excitation (P<0.05), whereas these two groups significantly increased levels compared with the normal group after excitation (P<0.05). No significant differences in IL-25 mRNA expression levels were detected in the dexamethasone and budesonide groups when compared with the normal group after excitation. Therefore, we conclude that IL-25 is involved throughout the process of inflammation and inflammatory immune pathogenesis in asthma. One of the mechanisms of glucocorticoid action in asthma may involve inhibition of IL-25 expression.

Entities:  

Keywords:  asthma; budesonide; dexamethasone; glucocorticoid; interleukin-25

Year:  2016        PMID: 28352347      PMCID: PMC5348697          DOI: 10.3892/etm.2016.4002

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  19 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Heat denaturation affects the ProDer p 1 IgE reactivity and downregulates the development of the specific allergic response.

Authors:  Mauro Magi; Lida Garcia; Michel Vandenbranden; Rémi Palmantier; Alain Jacquet
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

3.  Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model.

Authors:  Yu Jin Oh; Jangwook Lee; Ji Young Seo; Taiyoun Rhim; Sang-Heon Kim; Ho Joo Yoon; Kuen Yong Lee
Journal:  J Control Release       Date:  2010-11-09       Impact factor: 9.776

4.  IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice.

Authors:  Tomohiro Tamachi; Yuko Maezawa; Kei Ikeda; Shin-Ichiro Kagami; Masahiko Hatano; Yohei Seto; Akira Suto; Kotaro Suzuki; Norihiko Watanabe; Yasushi Saito; Takeshi Tokuhisa; Itsuo Iwamoto; Hiroshi Nakajima
Journal:  J Allergy Clin Immunol       Date:  2006-06-21       Impact factor: 10.793

5.  Blocking induction of T helper type 2 responses prevents development of disease in a model of childhood asthma.

Authors:  J S Siegle; N Hansbro; C Dong; P Angkasekwinai; P S Foster; R K Kumar
Journal:  Clin Exp Immunol       Date:  2011-04-19       Impact factor: 4.330

6.  [IL-25 derived from epithelial cells has the potential to promote airway remodeling in asthma].

Authors:  Fen Liu; Jin-xiang Wu; Ji-ping Zhao; Hong-jia Li; Wen Liu; Wen-xiang Bi; Liang Dong
Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi       Date:  2012-06

Review 7.  Newer glucocorticosteroids and corticosteroid resistance reversal in asthma.

Authors:  Sukhbir K Shahid
Journal:  Pharm Pat Anal       Date:  2013-05

8.  New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25.

Authors:  Stephen D Hurst; Tony Muchamuel; Daniel M Gorman; Jonathan M Gilbert; Theresa Clifford; Sylvia Kwan; Satish Menon; Brian Seymour; Craig Jackson; Ted T Kung; Joan K Brieland; Sandra M Zurawski; Richard W Chapman; Gerard Zurawski; Robert L Coffman
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

9.  Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract.

Authors:  Alexander M Owyang; Colby Zaph; Emma H Wilson; Katherine J Guild; Terrill McClanahan; Hugh R P Miller; Daniel J Cua; Michael Goldschmidt; Christopher A Hunter; Robert A Kastelein; David Artis
Journal:  J Exp Med       Date:  2006-04-10       Impact factor: 14.307

10.  Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma.

Authors:  Sarah J Ballantyne; Jillian L Barlow; Helen E Jolin; Puneeta Nath; Alison S Williams; Kian Fan Chung; Graham Sturton; See Heng Wong; Andrew N J McKenzie
Journal:  J Allergy Clin Immunol       Date:  2007-09-24       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.